Travis Johnson of the IACC talks to NGP about the global problem of counterfeit pharmaceuticals.
The financial crisis and increasing regulatory restrictions make the pharma industry a tough battleground. GSK's Keith Allen tells NGP why innovative processes in the manufacturing line and ensuring regulatory harmony will create the winners in the industry.
With patent expiries due on some of the industry's biggest-selling drugs, pharmaceutical research and development has never been so important to the industry. What's more, in just the last two weeks, a plethora of Big Pharma companies have executed dramatic R&D strategies, highlighting just how critical the process has become.
Reports suggest that blockbuster drugs - defined as a drug that generates more than $1 billion of revenue each year - are beginning to wane. Are the reports true? And if so, how can pharma shift its focus to compensate potentially massive losses?
With counterfeit drugs becoming a very real problem for the pharmaceutical industry, EFPIA has announced Swedish trials of a new system aimed at combating the growth of this increasingly significant threat.